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[57] ABSTRACT 
This invention concerns a method for extending the survival 
time of mammalian lung tissue subjected to ischemia, by 
which said tissue is perfused with a preservation solution 
comprising a therapeutic dose of the delta opioid DADLE 
([D-Ala2,D-Leu5]-Enkephalin) under hypothermic condi 
tions. 
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METHOD FOR EMPLOYING THE DELTA 
OPIOID DADLE TO EXTEND TISSUE 
SURVIVAL TIME DURING ISCHEMIA 
FIELD OF THE INVENTION 
During the past thirty years, several methods have been 
developed for preserving solid organs for transplantation. In 
almost all cases, such preservation methods have included 
?ushing or perfusing organs with cold crystalloid or plasma 
solutions. The recent introduction of the University of 
\Vrsconsin Solution now permits kidneys to be stored for 72 
hours and livers for 24 hours in animal studies. However, 
safe preservation times for the heart and lungs are still 
limited to 4 to 6 hours regardless of the solution used 
(including University of Wisconsin Solution, Collins 
Solution, Euro-Collins Solution, or these solutions with 
many additives). 
In the last few years, our group found that a delta opioid, 
DADLE ([D-Ala2, d-Leu5]-Enkephalin), could extend tissue 
survival time substantially during normothermic multiple 
organ preservation. Because very few groups in the world 
use normothermic multiple organ techniques, the use of the 
DADLE in normothermic preparations is currently still 
limited. 
BACKGROUND OF THE INVENTION 
An acute shortage of donor organs greatly limits access to 
transplantation. As of Jul. 22, 1992, according to the United 
Network for Organ Sharing (UNOS), 21,120 patients were 
awaiting a kidney; 2,183 a liver; 783 a pancreas; 2,557 a 
heart; 166 a heart-lung; and 889 a lung transplant. Since 
December 1986, the demand for transplantation has 
increased by 188%, from 9,632 to 27,678 potential recipi 
ents. Meanwhile, there has been little change in the supply 
of organ donors. Between 1986 and 1991, the number of 
donors has been between 4,000 and 4,500 annually. As a 
result, the number of patients who die while awaiting a 
transplant continues to increase: from 1,537 in 1988 to 2,077 
in 1990, with variation according to the procedure required. 
The paucity of donor organs for human transplantation 
can be remedied to a certain extent by procuring organs from 
distant sites, particularly from large urban areas where 
accident rates are high. Heart and lung transplantations 
would bene?t greatly, as has been the case for renal 
transplantation, from the development of satisfactory meth 
ods of organ preservation to extend the travel time of donor 
organs. 
The criteria for lung donors are very strict; only 10% to 
15% of suitable heart donors will also be potential lung 
donors. With current clinical methods of lung preservation, 
4 to 6 hours of storage proves largely successful, and 
sometimes a period of ischernia of up to 9 hours is tolerated 
with depressed lung function after transplant. Several inves 
tigators have reported preservation for periods ranging from 
20 to 48 hours, but none of these reports has been associated 
with consistent, reliable results, which would be required for 
clinical application. Methods with such a short preservation 
time have three primary disadvantages: (1) they limit the 
geographic area from which grafts can be obtained; (2) they 
limit the time available for histocompatibility tests; and (3) 
they increase the likelihood of inadequate organ function 
after transplantation. 
Clinical methods used for lung preservation for transplan 
tation have included immediate implantation (donor trans 









thermic atelectasis, hypothermic pulmonary artery ?ushing 
and storage, with or without varying degrees of in?ation; 
donor core cooling on cardiopulmonary bypass; and autop 
erfused heart-lung preparation at norrnothermia. 
Single-?ush perfusion of the lungs is currently the most 
widely practiced technique in lung preservation. However, 
when simple ?ushing with preservation solution is used, the 
result is always unsatisfactory. Even with many di?erent 
additives and modi?cations to the solution, lung function is 
severely compromised after more than 12 hours of preser 
vation. For years, numerous chemicals (such as 
prostaglandins, oxygen free-radical scavengers, platelet acti 
vating factor antagonists or leukocyte depletion, 
corticosteroids, and other chemicals) have been added to 
pulmonary artery ?ush solutions such as modi?ed Euro 
Collins solution, University of Wisconsin solution, UCLA 
solution, Stanford solution, and Bretschneider’s solution. 
Although various reports have indicated that these added 
chemicals provide improved e?rects, no additive has been 
proved reliable. Our results from Group 2 (described 
elsewhere) appear to agree with previous studies. Euro 
Collins solution alone is known to cause pulmonary 
vasoconstriction, and the safe preservation time is usually 4 
to 6 hours. 
Long-termpreservation of donor organs in vitro will also 
make it possible to treat the donor organ before it is 
transplanted, thus reducing or possibly eliminating the 
necessity for immunosuppressive treatment of the recipient. 
Our previous study showed that DADLE can eifectively 
extend tissue survival time in a normothermic multiorgan 
preservation block. Because of technical dif?culties, normo 
thermic multiple organ preparations are used by only a few 
groups around the world; the use of DADLE in such 
preparations is limited at the present time. However, if 
DADLE can also extend tissue survival time in hypothermic 
storage, the potential of adding positive eifects to presently 
used preservation solutions will be tremendous. Not only 
will this technique improve hypothermic organ preservation, 
but it will also improve the effectiveness of various currently 
used cardioplegic solutions and possibly of other hypother 
mic treatment modalities. ' 
SUMMARY OF THE INVENTION 
This invention involves a method for extending the sur 
vival time of mammalian lung tissue subjected to ischemia, 
such as that which occurs during cardioplegia during open 
heart surgery and treatment of shock. This method com 
prises ?ushing the lung tissue with a preservation solution 
comprising a therapeutic dose (e.g., 1 to 10 mg/Kg) of the 
delta opioid DADLE ([D-Ala2, d-Leu5]-Enkephalin) and 
then preserving the lung in hypothermia. The results 
obtained have been very encouraging. 
Our rat lung preservation study indicated that when 
DADLE was added to the Euro-Collins solution, the lungs 
preserved for 24 hours maintained excellent function, a 
result never achieved by previous reports using Euro-Collins 
solution alone. 
Severe pulmonary edema, hemorrhage, and occlusive 
pulmonary artery resistance occurred in Group 2 (without 
DADLE) within 30 minutes of perfusion. Perfusion studies 
were carried out for more than 60 minutes in Group 1 
(Normal) and Group 3 (with DADLE). Pulmonary blood 
, ?ow was lower in Group 2 than in either Group 1 or Group 
65 3. Pulmonary vascular resistance (PVR) was much higher in 
Group 2 than in Groups 1 and 3 (p<0.05, FIG. 1). Airway 
pressure and airway resistance (AWR) were much higher in 
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Group 2 than in Group 1 and Group 3 (p<0.05). AWR was 
also higher in Group 3 than in Group 1 after 20 minutes of 
perfusion (p<0.05. FIG. 2). Oxygen tensions from the pul 
monary vein (pvO2) of the isolated lung in Group 2 were 
lower than those in Group 1 and Group 3 (p<0.05, FIG. 3). 
Alveolar-arterial oxygen difference was much higher in 
Group 2 than in Group 1 and Group 3 (p<0.05, FIG. 4). Lung 
tissue wet/dry weight ratio after perfusion was much higher 
in Group 2 than in Group 1 and Group 3 (FIG. 5). The most 
interesting ?nding is the near-normal tissue wet/dryweight 
ratio, pulmonary blood ?ow, pulmonary vascular resistance, 
and oxygen transporting capacity of the lungs after 24-hour 
preservation in the group using DADLE. In comparison with 
normal lungs (without preservation), airway resistance in the 
lungs preserved with DADLE increased slightly after pres 
ervation. However, this resistance was much lower than that 
of the lungs preserved with Euro-Collins solution alone. 
The results clearly demonstrate, for the ?rst time, that 
DADLE can effectively enhance hypothermic lung preser 
vation in rats. 
The mechanism by which DADLE extends tissue survival 
time is not at all clear. Because of the complexity of opioids 
and their receptors, studies to date have primarily concen 
trated on the reactions of different opioids with di?erent 
receptors. Studies of the eifects of opioids on the cardio 
vascular system have been performed for years, but the 
results are very controversial. Through a Medline search, we 
have found no reports relating opioid agonists to tissue 
metabolism or organ preservation other than those we our 
selves have published. Delta opioid receptors may be 
responsible for naturally occurring animal hibernation, 
because continuous subcutaneous administration of 
naloxone, an opioid antagonist, diminished the frequency 
and length of hibernation bouts in ground squirrels. This 
indicates that animal hibernation may be induced by a 
mechanism involving an endogenous opioid that acts 
through binding to receptor sites. 
We can only speculate about possible mechanisms by 
which DADLE extends tissue survival time during hypoth 
ermia. The effect may be related either to the inhibitory 
effect of DADLE on tissue metabolism, or to the ability of 
DADLE to protect tissue from various types of damage 
during ischemia. The results of our study indicated that the 
improved preservation may also be related to the effect of 
DADLE on vasodilation, as shown by low vascular resis 
tance after preservation. This supposition is also supported 
by our previous experiment, in which severe reduction of 
arterial blood pressure occurred after intravenous injection 
of DADLE into anesthetized animals. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Comparison of pulmonary vascular resistance 
(PVR) in three groups of rat lungs (the lower the better). 
FIG. 2. Comparison of airway resistance in the same three 
groups of rat lungs (lower is better). 
FIG. 3. Comparison of oxygen tensions in the isolated 
pulmonary vein in the three groups of rat lungs (higher is 
better). 
FIG. 4. Comparison of alveolar-arterial oxygen diiference 
in the three groups of rat lungs (lower is better). 
FIG. 5. Lung tissue wet/dryweight ratios after preserva 










DETAILED DESCRIPTION OF THE 
INVENTION 
METHODS 
Healthy adult rats (250 to 300 gm) were allowed free 
access to food and water before surgery. All animals 
received humane care in compliance with the “Principles of 
Laboratory Animal Care” formulated by the National Soci 
ety for Medical Research and the “Guide for the Care and 
Use of Laboratory Animals” prepared by the Institute of 
Laboratory Animal Resources and published by the National 
Institutes of Health (NIH publication No. 86-23, revised 
1985). 
Preparation of hypothennic isolated lung storage: 
The rats were anesthetized by intraperitoneal injection of 
sodium pentobarbital (35 to 50 mg/kg wt). The cervical 
trachea was cannulated, and each animal was ventilated by 
a rodent respirator using room air. Tidal volume of 2.5 to 3.5 
ml and rate of 40 to 50 rpm were maintained. The retroster 
nal space was exposed by blunt dissection, and two large 
straight clamps were applied in a parallel fashion across the 
sternum. Care was taken not to injure the lungs and vessels 
beneath. The thorax was opened by median stemotomy. 
After administration of 300 IU heparin iv, the inferior 
pulmonary ligaments were carefully divided. The left supe 
rior vena cava was dissected, ligated, and divided. The hilum 
of the left lung was approached anteriorly, and the vessels 
and bronchus were separated by blunt dissection. The left 
pulmonary artery was dissected, and a suture was placed 
around it. The main pulmonary artery was transected 
through the transverse sinus, and a cannula was placed in the 
left pulmonary artery through the transected main pulmo 
nary artery. The suture around the left pulmonary artery was 
tied, and the left atrium was partly excised to decompress the 
left atrium. The left lung was ?ushed with cold preservation 
solution, removed, and preserved at 4° C. for 24 hours 
before functional studies. This simulates removing a lung 
from a donor, said lung being preserved before being trans 
planted into a second individual needing a new lung. 
Technique of isolated lung function studies. 
A perfusion apparatus consisting of a living host rat and 
a temperature-controlled, humidi?ed chamber was used for 
isolated lung function studies. The host rat was anesthetized 
by intraperitoneal injection of sodium pentobarbital (35-5O 
mg/kg wt). The cervical trachea was cannulated, and the 
animal was ventilated by a rodent respirator using room air. 
Tidal volume of 2.5 to 3.5 ml and rate of 40 to 50 rpm were 
used. The right internal jugular Vein was cannulated with a 
2-mm catheter. Heparin sodium 3 mg/kg was infused 
intravenously, and both carotid arteries were cannulated 
with 0.5-mm catheters. The catheter in the right carotid 
artery was connected to a Gould pressure transducer for 
arterial blood pressure monitoring. Blood from the host rat 
was withdrawn by gravity from the right internal jugular 
vein to the pulmonary artery of the isolated lung. The 
isolated lung was perfused with host venous blood by using 
a hydrostatic pressure of 25 mmHg. The isolated lung was 
suspended in a perfusion chamber, which was immersed in 
a 37° C. water bath. Blood returned from the isolated lung 
was collected in the perfusion chamber. A roller pump 
returned the blood from the perfusion chamber to the left 
carotid artery of the host rat. The rate of blood returning 
from the chamber was adjusted to maintain satisfactory 
systemic pressure. 
During the perfusion period, the isolated lung was ven 
tilated with room air at respiratory rate of 40 to 50 rpm, tidal 
volume of 2.5 ml, and PEEP of 0.5 cm H2O. Such ventilation 
and perfusion may, for example, be applied to an isolated 
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lung wherein ischernia occurs during cardioplegia during 
open-heart surgery and treatment of shock. 
After an initial 5- to 10-minute equilibration period, blood 
samples from the pulmonary artery and vein were taken 
every 10 minutes for blood gas analysis. Perfusion pressure, 
perfusion ?ow, airway pressure, and tidal volume were 
recorded. Through the use of these parameters, puhnonary 
vascular resistance and airway resistance were calculated At 
the end of the experiment, lung tissue samples were taken 
for wet/dry weight ratio measurements. 
Experimental Results 
Animal groups studied 
Twenty-four rats were used in this study. The rats were 
divided into three groups. Group 1 (N=8) was used as 
normal controls, in which the left lung was removed and 
immediately transferred to the perfusion apparatus for func 
tion studies. In this group, no interruption of ventilation 
occurred, and interruption of lung blood perfusion was 
routinely less than 10 to 20 seconds. Lung function in this 
group was assumed to be normal. In Group 2 (N=8), the left 
lung was ?ushed with 10 to 15 ml of 4° C. Euro-Collins 
solution at a gravity gradient of 20 cm H20 and immersed 
in 4° C. Euro-Collins solution for 24 hours. In Group 3 
(N=8), the left lung was also flushed with 10 to 15 ml of 4° 
C. Euro-Collins solution, followed by 3 to 5 ml of 4° C. 
DADLE solution (1 mg/Kg, Peninsula Lab, Behnont, 
Calif). and then immersed in 4° C. Euro-Collins solution for. 
24 hours. In Groups 2 and 3, the bronchus was clamped at 
the end of inspiration to keep the lung in?ated during 
storage. 
Statistical analysis. 
Two-way analysis of variance (ANOVA) was used for 
repeated measurements. If signi?cance was established, the 
Student-Newman-Keuls test was used to analyze the differ 
ence between individual groups. A value of p<0.05 was 
considered signi?cant. All results were expressed as 
meansi-SEM. 
Overall performance. 
Severe pulmonary edema and hemorrhage occurred in 
Group 2 (Euro-Collins solution only) within 30 minutes of 
perfusion. and no preparation could be perfused for more 
than 30 minutes. This phenomenon did not occur in either 
Group 1 (normal) or Group 3 (Euro-Collins plus DADLE), 
and perfusion studies could be carried out for more than 60 
minutes in these two groups. Oxygen tension and carbon 
dioxide tension in the pulmonary artery and vein of the 
isolated lung during the 60-minute reperfusion period 
remained stable and were very comparable between Group 
1 and Group 3. Pulmonary vascular resistance and airway 
resistance were also stable during the perfusion period in 
these two groups. 
Blood ?ow and pulmonary vascular resistance (PVR) of the 
isolated lung. 
Pulmonary blood ?ow ranged from 1.91i0.27 to 
3.31i0.53 rnl/min in Group 1; 0.6li0.10 to 0.82i0.10 
rnl/rnin in Group 2; and 1.68i0.09 to 1.94i0.21 ml/min in 
Group 3. Pulmonary blood ?ow was lower in Group 2 than 
in Group 1 and Group 3. In Group 1, PVR ranged from 
7.5i0.8 to 14?.6 mmHg/ml/min. In Group 2. it ranged from 
365 to 54:11 mmHg/ml/min; and in Group 3, it ranged 
from 13.6i1 to 15i1 mmHg/ml/min. Because of very high 
pulmonary vascular resistance in Group 2 (p<0.05 as com 
pared to Group 1 and Group 3). perfusion could not be 
continued after 30 minutes, indicating severe tissue edema 
in this group. No signi?cant di?erence was found in pul 
monary vascular resistance between Group 1 and Group 3 
(FIG. 1). 
Airway pressure and resistance (AWR) of the isolated lung. 
When a tidal volume of 2.5 ml was used, airway pressure 








to 18.4i1.1 mmHg in Group 2; and 9.5111 to 13.3i1.2 mm 
Hg in Group 3. Airway pressure was much higher in Group 
2 (p<0.05 as compared to Group 1 and Group 3). It was also 
higher in Group 3 than in Group 1. 
AWR in Group 1 ranged from 2.6i0.2 to 3.7i'0.5 InmHg/ 
ml. It ranged from 5.5i0.3 to 7-_l'0.4 mmHg/ml in Group 2 
and from 3.7i0.3 to 5.0105 mmHg/ml in Group 3. AWR 
was much higher in Group 2 than in Groups 1 and 3 
(p<0.05). However, AWR was also higher in Group 3 than 
in Group 1 after 20 minutes of perfusion (p<0.05, FIG. 2). 
Blood gases in the in?ow and out?ow of the isolated lung. 
Mean oxygen tensions in the pulmonary artery (before 
oxygenation) were 33il.6 to 36i2.1 for Group 1; 485 to 
52i7 for Group 2; and 5314.0 to 605.7 for Group 3. Mean 
oxygen tensions from the pulmonary vein (after oxygenation 
by the isolated lung) were 130i'l3 to 180i11 mmHg for 
Group 1; 70i9.0 to 92i14 in Group 2; and 116:8.0 to 
173?1 in Group 3. Oxygen tensions in Group 2 were lower 
than in Group 1 and Group 3 during perfusion and became 
worse when perfusion time was longer, indicating impaired 
oxygenation capacity in Group 2 (FIG. 3). Carbon dioxide 
tensions in the pulmonary artery (before the blood was 
oxygenated by the isolated lung) were 30i2.7 to 38i2 in 
Group 1; 41i4 to 41¢? in Group 2; and 1&2 to 233 in 
Group 3. Carbon dioxide tensions in the pulmonary vein 
(after the blood was oxygenated by the isolated lung) were 
17i'0.6 to 19i2.0 in Group 1; 17i2.5 to 23:4 in Group 2; 
and 16i2 to 235 in Group 3. No statistically signi?cant 
difference was found among the three groups, although 
perfusion time was much shorter in Group 2. 
Alveolar-arterial oxygen di?erence: 
Alveolar-arterial oxygen difference (A-aO2 di?’erence) 
ranged from 4.68i4.62 to 3029x1028 mmHg in Group 1. 
It ranged from 44.01il0.94 to 54.88i6.16 mmHg in Group 
2, and from 0.46%.46 to 23.495.45 mmHg in Group 3. 
A-aO2 difference was much higher in Group 2 than in either 
Group 1 or Group 3 (p<0.05, FIG. 4). 
Lung tissue wet/dry weight ratio after perfusion. 
Lung tissue wet/dry weight ratio after perfusion was 
6.3i0.4 in Group 1. It was 8.7i0.5 in Group 2 and 5.7i0.7 
in Group 3. Tissue wet/dry weight ratio was much higher in 
Group 2 than in Group 1 and Group 3 (p=0.005), even 
though the perfusion time was only 30 minutes in Group 2. 
There was no difference in tissue wet/dry weight ratio 
between Group 1 and Group 3. See FIG. 5. 
In summary, the present invention clearly demonstrates 
that DADLE has a very positive e?iect on hypothermic rat 
lung preservation. On the basis of the described experimen 
tal work and other published and unpublished observations 
involving representative animals (i.e., rodents and canines), 
the conclusions reached herein are believed generally appli 
cable to mammals as a group. The mechanism of this effect 
is not clear and deserves further study. 
Composition of several preservation solutions 
Collins M solution 
Potassium 115 mmol/L 
Sodium 10 mmol/L 
Chloride 15 mmol/L 
Phosphate 13 mmol/L 
Bicarbonate 10 mmol/L 
Magnesium 3 mmol/L 
Glucose 139 mmol/L 
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Euro-Collins solution 
Sodium 10 mmol/L 
Potassium 115 mmol/L 
Chloride 15 mmol/L 
Bicarbonate 10 mmol/L 
Phosphate 58 mmol/L 
Glucose 38.5 g/L 
University of Wisconsin solution 
Sodium 27 mmol/L 
Potassium 115 mmol/L 
Chloride 0 mmol/L 
Phosphate 25 mmol/L 
Magnesium 5 mmol/L 
Raf?nose 30 mmol/L 
Lactobionate 100 mmol/L 
Adenosine 1.3 g/L 
Glutathione 09 g/l 
Allopurinol 0.1 g/l 
Hydroxyethyl starch 50 g/l 
I claim: 
1. A method for extending the survival time of at least one 
isolated mammalian lung subjected to ischemia and 





perfusion with a preservation solution comprising a preser 
vation effective amount of the delta opioid DADLE ((D 
Alaz. D-Leu5)-Enkephalin) at a hypothermic temperature. 
2. The method of claim 1 wherein the amount of DADLE 
in the preservation solution is within the range of 1 to 10 
mg/Kg. 
3. The method of claim 1 wherein the hypothermic 
conditions include the temperature being maintained at 4° C. 
4. The method of claim 2 wherein the hypothermic 
conditions involve the temperature being maintained at 4° C. 
5. The method of claim 4 wherein the lung is etfectively 
preserved for at least 24 hours without the loss of function. 
6. The method of claim 1 wherein the preservation 
solution is Euro-Collins solution. 
7. The method of claim 1 wherein the lung has been 
removed from a donor and is being preserved before being 
transplanted into a second individual needing a new lung. 
8. The method of claim 1 wherein the ischemia occurs 
during cardioplegia during open-heart surgery and treatment 
of shock. 
9. The method of claim 8 wherein the isolated lung is also 
ventilated during the perfusion period. 
